A new study published in The Lancet Diabetes & Endocrinology has provided significant evidence that sotagliflozin, a recently approved medication for type 2 diabetes and kidney disease, can reduce the risk of heart attacks and strokes among patients with these conditions. Conducted by researchers led by Mount Sinai, the SCORED trial analyzed 10,584 patients with chronic kidney disease, type 2 diabetes, and cardiovascular risk factors.
The results showed that sotagliflozin reduced the rate of heart attacks, strokes, and deaths from cardiovascular causes by 23% compared to a placebo. This finding is significant because other SGLT inhibitors, which are commonly used for diabetes and kidney disease, do not have this level of effect on cardiovascular risk.
The study’s chair, Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI, noted that the benefits seen with sotagliflozin are distinct from those seen with other SGLT2 inhibitors and provide a new mechanism of action for reducing cardiovascular risk.
The study’s findings have important implications for patients with heart failure or type 2 diabetes who also have chronic kidney disease and cardiovascular risk factors. Physicians now have a new option to reduce global cardiovascular risk, including the reduction of heart attacks and strokes.
Source: https://www.eurekalert.org/news-releases/1073500